Sep 2026· Transplantation and Cellular Therapy· 2 citations
Medicine
TL;DR
Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.
Abstract
Background
Allogeneic hematopoietic cell transplantation is the only curative treatment for myelofibrosis, but failure occurs by two mechanistically distinct routes: relapse of the neoplasm, which reflects its underlying genetics, and non-relapse mortality, which reflects whether the patient and graft tolerate the procedure. Established prognostic systems either lack molecular granularity or were derived in the non-transplant setting, and all collapse these two routes into a single survival estimate. None can indicate why an individual patient is at risk, or which class of intervention might reduce that risk.
Objective
To determine why an individual patient is at risk and to develop and validate an integrated framework that quantifies biology- and patient-driven prognosis.
STUDY
Design
We analyzed 1,550 adults undergoing first allogeneic transplantation for primary or secondary myelofibrosis across international centers, the largest genomically annotated transplant cohort in this disease. The cohort was split into development (n=930) and validation (n=620) sets. Overall survival was modeled by Cox regression; relapse and non-relapse mortality were modeled as competing events by Fine-Gray subdistribution-hazard regression at 2 years. Discrimination was assessed by the concordance index with bootstrap confidence intervals. The molecular contribution was quantified by variance decomposition of, and robustness to the analytic choices was examined by resampling.
Results
A genetically defined disease-intrinsic axis, including TP53 allelic state, RAS pathway mutations, ASXL1 and driver genotype, blasts and blood counts, predicted 2 year relapse incidence (validation concordance 0.69, 95% CI 0.63 to 0.74), whereas a non-overlapping host and structural axis, including portal vein thrombosis, donor type, patients' performance status, and age predicted 2-year non-relapse mortality (0.63, 95% CI 0.59 to 0.68). The two scores shared only 3.4% of their variance, indicating that a patient's disease genetics carried almost no information about non-relapse mortality. Variance decomposition showed that TP53 allelic state alone accounted for 30% of the relapse score. Recombined, the framework discriminated overall survival (concordance 0.640, 95% CI 0.616 to 0.662) better than every established prognostic system. For proof of concept, 3 risk groups separated in the validation cohort, with 5 year survival of 72%, 58%, and 39% (P<0.001), and the models were well calibrated.
Conclusions
Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions. Estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making. The calculator is openly available (https://imtss-calculator.com).
BACKGROUND
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population-level outcomes remain...
M. Brink, Arie C. van der Spek, J. Doorduijn et al.· European Journal of Haematol...· 0 citations
Follicular lymphoma (FL) has traditionally been considered an incurable malignancy characterized by repeated relapses. However, emerging long-term data are increasingly challenging this paradigm. With rituximab, median overall survival approaches 20 years, and only 35-40% of patients require more than one treatment lin...
L. Magnano, A. López-Guillermo, Matthew J. Maurer· Blood· 0 citations
Actionable pharmacogenetic variants are highly prevalent in alloHCT-recipients and future studies should investigate whether genotype-guided drug selection and dosing could improve outcomes in alloHCT recipients.
Lea P. A. Timmann, Pauline Lanting, L. Morsink et al.· Hemato· 0 citations
Simple Summary Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) is a recently recognized overlap entity that exhibits biological and clinical features intermediate between myelodysplastic syndromes and acute myeloid leukemia. Its emergence has challenged the application of traditional prognostic systems develo...
M. Liga, Angeliki N. Georgopoulou, D. Tsokanas et al.· Cancers· 0 citations
Venetoclax plus azacitidine has demonstrated substantial clinical activity in treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS), including high rates of complete remission, marrow complete remission, and overall response. However, recent phase 3 experience indicates that greater response depth does not nec...
Xin-Fu Zou, Jin-Yang Bu, Ao-Jiao Chu et al.· Frontiers in Medicine· 0 citations
Acute myeloid leukemia, myelodysplasia-related (AML-MR), represents a genetically defined and clinically heterogeneous entity characterized by myelodysplasia-related gene (MRG) mutations, specific cytogenetic abnormalities, and frequently a previous history of myelodysplastic syndromes (MDS) or MDS/myeloproliferative n...
Giuseppe G. M. Leone, U. Testa, E. Attardi et al.· Mediterranean Journal of Hem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.